Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Identification and validation of a prognostic proteomic signature for cervical cancer.

Rader JS, Pan A, Corbin B, Iden M, Lu Y, Vellano CP, Akbani R, Mills GB, Simpson P.

Gynecol Oncol. 2019 Aug 30. pii: S0090-8258(19)31473-8. doi: 10.1016/j.ygyno.2019.08.021. [Epub ahead of print]

PMID:
31477280
2.

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.

Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB.

Cancer Cell. 2019 Jun 10;35(6):851-867.e7. doi: 10.1016/j.ccell.2019.05.001.

PMID:
31185210
3.

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.

Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, Feng N, Vellano CP, Federico L, Marszalek JR, Mills GB, Hanke J, Ramaswamy S, Wang J.

Sci Rep. 2019 Feb 12;9(1):1853. doi: 10.1038/s41598-019-38534-6.

4.

Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.

Ip CKM, Ng PKS, Jeong KJ, Shao SH, Ju Z, Leonard PG, Hua X, Vellano CP, Woessner R, Sahni N, Scott KL, Mills GB.

Nat Commun. 2018 Nov 2;9(1):4583. doi: 10.1038/s41467-018-06949-w.

5.

A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.

Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N; Cancer Genome Atlas Research Network, Weinstein JN, Mills GB, Levine DA, Akbani R.

Cancer Cell. 2018 Apr 9;33(4):690-705.e9. doi: 10.1016/j.ccell.2018.03.014. Epub 2018 Apr 2.

6.

Systematic Functional Annotation of Somatic Mutations in Cancer.

Ng PK, Li J, Jeong KJ, Shao S, Chen H, Tsang YH, Sengupta S, Wang Z, Bhavana VH, Tran R, Soewito S, Minussi DC, Moreno D, Kong K, Dogruluk T, Lu H, Gao J, Tokheim C, Zhou DC, Johnson AM, Zeng J, Ip CKM, Ju Z, Wester M, Yu S, Li Y, Vellano CP, Schultz N, Karchin R, Ding L, Lu Y, Cheung LWT, Chen K, Shaw KR, Meric-Bernstam F, Scott KL, Yi S, Sahni N, Liang H, Mills GB.

Cancer Cell. 2018 Mar 12;33(3):450-462.e10. doi: 10.1016/j.ccell.2018.01.021.

7.

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.

Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB.

Cancer Cell. 2018 Mar 12;33(3):401-416.e8. doi: 10.1016/j.ccell.2018.01.019.

8.

Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies.

Lee J, Geiss GK, Demirkan G, Vellano CP, Filanoski B, Lu Y, Ju Z, Yu S, Guo H, Bogatzki LY, Carter W, Meredith RK, Krishnamurthy S, Ding Z, Beechem JM, Mills GB.

Mol Cell Proteomics. 2018 Jun;17(6):1245-1258. doi: 10.1074/mcp.RA117.000291. Epub 2018 Mar 12.

9.

Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm.

McGrail DJ, Lin CC, Garnett J, Liu Q, Mo W, Dai H, Lu Y, Yu Q, Ju Z, Yin J, Vellano CP, Hennessy B, Mills GB, Lin SY.

NPJ Syst Biol Appl. 2017 Mar 6;3:8. doi: 10.1038/s41540-017-0011-6. eCollection 2017.

10.

Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.

Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB.

Sci Transl Med. 2017 May 31;9(392). pii: eaal5148. doi: 10.1126/scitranslmed.aal5148.

11.

A murine preclinical syngeneic transplantation model for breast cancer precision medicine.

Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, Vellano CP, Ju Z, Gagea M, Liu S, Mitra S, Dennison JB, Lorenzi PL, Cardnell R, Diao L, Wang J, Lu Y, Byers LA, Perou CM, Lin SY, Mills GB.

Sci Adv. 2017 Apr 19;3(4):e1600957. doi: 10.1126/sciadv.1600957. eCollection 2017 Apr.

12.

Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.

Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H.

Cancer Cell. 2017 Feb 13;31(2):225-239. doi: 10.1016/j.ccell.2017.01.005.

13.

Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.

Federico L, Jeong KJ, Vellano CP, Mills GB.

J Lipid Res. 2016 Jan;57(1):25-35. doi: 10.1194/jlr.R060020. Epub 2015 May 14. Review.

14.

Assembly and function of the regulator of G protein signaling 14 (RGS14)·H-Ras signaling complex in live cells are regulated by Gαi1 and Gαi-linked G protein-coupled receptors.

Vellano CP, Brown NE, Blumer JB, Hepler JR.

J Biol Chem. 2013 Feb 1;288(5):3620-31. doi: 10.1074/jbc.M112.440057. Epub 2012 Dec 17.

15.

Protease-activated receptor 1 (PAR1) coupling to G(q/11) but not to G(i/o) or G(12/13) is mediated by discrete amino acids within the receptor second intracellular loop.

McCoy KL, Gyoneva S, Vellano CP, Smrcka AV, Traynelis SF, Hepler JR.

Cell Signal. 2012 Jun;24(6):1351-60. doi: 10.1016/j.cellsig.2012.01.011. Epub 2012 Jan 28.

16.

RGS14 at the interface of hippocampal signaling and synaptic plasticity.

Vellano CP, Lee SE, Dudek SM, Hepler JR.

Trends Pharmacol Sci. 2011 Nov;32(11):666-74. doi: 10.1016/j.tips.2011.07.005. Epub 2011 Sep 8. Review.

17.

G protein-coupled receptors and resistance to inhibitors of cholinesterase-8A (Ric-8A) both regulate the regulator of g protein signaling 14 RGS14·Gαi1 complex in live cells.

Vellano CP, Maher EM, Hepler JR, Blumer JB.

J Biol Chem. 2011 Nov 4;286(44):38659-69. doi: 10.1074/jbc.M111.274928. Epub 2011 Aug 31.

18.

Activation of the regulator of G protein signaling 14-Gαi1-GDP signaling complex is regulated by resistance to inhibitors of cholinesterase-8A.

Vellano CP, Shu FJ, Ramineni S, Yates CK, Tall GG, Hepler JR.

Biochemistry. 2011 Feb 8;50(5):752-62. doi: 10.1021/bi101910n. Epub 2011 Jan 11.

19.

RGS14 is a natural suppressor of both synaptic plasticity in CA2 neurons and hippocampal-based learning and memory.

Lee SE, Simons SB, Heldt SA, Zhao M, Schroeder JP, Vellano CP, Cowan DP, Ramineni S, Yates CK, Feng Y, Smith Y, Sweatt JD, Weinshenker D, Ressler KJ, Dudek SM, Hepler JR.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16994-8. doi: 10.1073/pnas.1005362107. Epub 2010 Sep 13.

Supplemental Content

Loading ...
Support Center